Engineering IgG-Like Bispecific Antibodies-An Overview

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Monoclonal antibodies are successful therapeutics, but their effector functions (e.g., ADCC, CDC) can be insufficient for robust anti-tumor immunity.
• Tumor cell resistance and insufficient immune activation limit long-term efficacy of monospecific antibody therapies.
• Bispecific antibodies can overcome these limitations by directly recruiting and activating T-cells at the tumor site.

Purpose of the Study:

• To review technologies enabling the generation of antibodies with dual specificities.
• To highlight the potential of bispecific antibodies in overcoming current therapeutic challenges in oncology and other indications.

Main Methods:

• This mini-review summarizes existing and emerging technologies for engineering bispecific antibodies.
• Focus on methods combining two distinct antibody paratopes from different heavy and light chains.

Main Results:

• Approved bispecific antibodies like Blinatumomab and Catumaxomab demonstrate clinical success in certain cancers.
• Emicizumab, a bispecific antibody for hemophilia A, received FDA approval, showcasing broader therapeutic applications.
• The engineering of bispecific antibodies presents significant challenges but is crucial for next-generation therapeutics.

Conclusions:

• Bispecific antibody technology is advancing, offering promising new therapeutic strategies.
• Overcoming engineering challenges is key to unlocking the full potential of dual-specific antibodies in medicine.
• Further development in bispecific antibody generation will expand treatment options for various diseases.